News

Aspira Pathlab & Diagnostics Limited submitted a compliance certificate to the BSE Limited under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by MUFG Intime India Private Limited, formerly Link Intime India Private Limited, the company’s Registrar & Share Transfer Agent.

Aspira Pathlab & Diagnostics Limited informed the BSE Limited that the trading window for dealing in the company`s securities will be closed for designated persons and their immediate relatives from October 1, 2026, until the declaration of financial results for the half year ended September 30, 2026, and 48 hours thereafter.

Aspira Pathlab & Diagnostics Limited will seek shareholder and statutory approvals to raise funds through the issuance of instruments including equity shares or warrants convertible into equity shares via preferential issue, private placements, rights issue, or other permitted methods, the company said in a filing to the BSE Limited on September 7, 2026.

Aspira Pathlab & Diagnostics Limited has informed the BSE Limited that its book closure will be from September 19, 2026, to September 25, 2026, for the purpose of the 53rd Annual General Meeting scheduled to be held on September 25, 2026, at 2:00 P.M. via video conferencing or other audio visual means. The e-voting period will be from 9:00 A.M. (IST) on September 22, 2026, to 5:00 P.M. (IST) on September 24, 2026, with a cut-off date of September 18, 2026.

Aspira Pathlab & Diagnostics will hold a meeting of the Board of Directors of the Company on 12 August 2026.